Literature DB >> 21281227

Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus.

Teresa Vela-Chávez1, Patrick Adam, Marcus Kremer, Karin Bink, Christopher M Bacon, Geetha Menon, Judith A Ferry, Falko Fend, Elaine S Jaffe, Leticia Quintanilla-Martínez.   

Abstract

The aims of this study were to analyze the incidence and morphology of cyclin D1+ DLBCL and cases of Richter transformation (RT), and to elucidate possible molecular mechanisms of cyclin D1 overexpression. Seventy-two cases of de novo DLBCL and 12 cases of RT were included in this study. Cyclin D1 positivity was found in 10/66 (15%) cases of unselected de novo DLBCL and in 2/11 (18%) cases of RT. Seven independently identified cases of cyclin D1+ DLBCL, including one RT, were added to the study. Centroblastic morphology was found in 17/19 (89%) cases of cyclin D1+, most with a post-germinal center phenotype (CD10-, BCL6+, MUM1+). No alterations in the CCND1 gene indicative for a translocation t(11;14) were identified by FISH. Analysis of the MYC locus yielded gene copy alterations in five cases and no disruption of the gene locus in any case, suggesting an alternative mechanism of cyclin D1 deregulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281227      PMCID: PMC6324544          DOI: 10.3109/10428194.2010.540361

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  13 in total

Review 1.  Aggressive B-cell lymphomas: how many categories do we need?

Authors:  Jonathan W Said
Journal:  Mod Pathol       Date:  2012-11-16       Impact factor: 7.842

Review 2.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

3.  Richter transformation with c-MYC overexpression: report of three cases.

Authors:  Ling Wang; Azadeh Aghel; Brandon Peterson; Jessica Wang-Rodriguez; Huan-You Wang; Xianfeng Frank Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

4.  Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma.

Authors:  Carla Fuster; David Martín-Garcia; Olga Balagué; Alba Navarro; Ferran Nadeu; Dolors Costa; Miriam Prieto; Itziar Salaverria; Blanca Espinet; Alfredo Rivas-Delgado; Maria José Terol; Eva Giné; Pilar Forcada; Margaret Ashton-Key; Xose S Puente; Steven H Swerdlow; Sílvia Beà; Elias Campo
Journal:  Haematologica       Date:  2019-11-21       Impact factor: 9.941

5.  A cyclin D1-positive diffuse large B-cell lymphoma of germinal center B-cell-like subtype in the right tonsil: A rare case report.

Authors:  Changrui Jiang; Xiuying Shi; Chuifeng Fan
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

6.  Prognostic efficacy of the human B-cell lymphoma prognostic genes in predicting disease-free survival (DFS) in the canine counterpart.

Authors:  Mohamad Zamani-Ahmadmahmudi; Sina Aghasharif; Keyhan Ilbeigi
Journal:  BMC Vet Res       Date:  2017-01-09       Impact factor: 2.741

7.  Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge.

Authors:  Da Gao; Zach Liu
Journal:  Biomark Res       Date:  2019-06-03

8.  CCND1 Genomic Rearrangement as a Secondary Event in High Grade B-Cell Lymphoma.

Authors:  Jinjun Cheng; Mohamed Amin Hashem; Frederic Barabé; Stéphanie Cloutier; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  Hemasphere       Date:  2020-12-09

Review 9.  How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.

Authors:  José Cabeçadas; Victor E Nava; Joao L Ascensao; Maria Gomes da Silva
Journal:  Curr Oncol       Date:  2021-11-11       Impact factor: 3.677

10.  Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.

Authors:  Zhen Jin; Kai Qing; Yuan Ouyang; Zhao Liu; Wenfang Wang; Xiaoyang Li; Zizhen Xu; Junmin Li
Journal:  J Exp Clin Cancer Res       Date:  2016-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.